National Registry May Reduce Mortality Among Alloimmunized People with Sickle Cell Disease
A nationwide red blood cell alloantibody exchange could reduce mortality among alloimmunized individuals with sickle cell disease, according to study results presented at ASH Annual Meeting and Exposition. Use of a national system to share data from blood transfusions also could reduce the cost of care for this population, investigators concludedSource: Healio
Sickle Cell Cure will be Cost-Effective if Health Disparities Considered -Study Finds
Dec 13 (Reuters) - Multimillion-dollar gene therapies being tested for sickle cell disease will be cost-effective in the United States if health disparities tied in part to decreased access to healthcare are taken into account, researchers said at a meeting of blood-disease specialists.Source: Reuters
The Unknown Puts Offspring At Risk Of Sickle Cell Disease
Most Connecticut residents who carry a trait for sickle cell disease don’t know it, resulting in thousands of people unwittingly risking having a child born with the debilitating illness, according to sickle cell disease specialists.Source: CT News Junkie
Sickle Cell Disease Has Long Been Misunderstood. These Firefighters Want to Change That.
The history of sickle cell disease goes back about 4,000 years to when humans began harvesting rice, according to Dr. Lakshmanan Krishnamurti, an MD in Hematology-Oncology at Yale New Haven Children’s hospital.... Sickle cell disease has long been misunderstood. These firefighters want to change that. New Haven Fire Department Lt. Samod Rankins, James Rawlings, president and CEO of Sickle Cell Disease Association of America, Connecticut, and retired New Haven Fire Department Capt. Gary Tinney.Source: New Haven Register
ExPath Grad Student Madeline Mayday Awarded Grant from the NIDDK Cooperative Centers of Excellence in Hematology
Madeline Mayday, BS, a fourth-year Experimental Pathology graduate student in the Laboratory of Diane Krause, MD, PhD, was recently awarded a 2022 National Institute of Diabetes and Digestive and Kidney Diseases Hematology Centers Program Type B Pilot and Feasibility grant
Stem Cell Treatment Offers Hope — And High Costs — For Retired Farmington Teacher With Aggressive Forms Of Cancer
John has been at Yale New Haven Hospital since the beginning of July to prepare, undergo and recover from a stem-cell transplant to treat non-Hodgkin Lymphoma. His recovery is going as planned, but isn’t an easy road.Source: Yahoo! News
Health & Veritas: Hope for Sickle Cell Patients (Ep. 25)
On the Health & Veritas podcast, Yale physician-professors Howard Forman and Harlan Krumholz talk about the latest news and ideas in healthcare and seek out the truth amid the noise. In the latest episode, they’re joined by Dr. Lakshmanan Krishnamurti, chief of pediatric hematology and oncology at the Yale School of Medicine and an expert on sickle cell disease.Source: Yale Insights
Bernard G. Forget Hematology Scholars Program Supported by Friends who Give
Mary Alice and Thomas O’Malley’s recent gift to support Yale’s Bernard G. Forget Hematology Scholars Program is rooted in multiple friendships. The couple learned about the program from their friend Alan Lebowitz, MD., who was Associate Clinical Professor of Medicine at Yale School of Medicine and is a retired Connecticut hematologist. Dr. Lebowitz, a champion of Yale Cancer Center, was also a close friend of the Scholars Program’s late namesake.
Convalescent Plasma for Severe COVID-19: D-Dimer Level After Transfusion May Be a Predictive Biomarker of Mortality
Researchers characterized the outcomes seen in patients hospitalized with severe coronavirus disease 2019 (COVID-19) after infusion with convalescent plasma (CP), and the results were presented during the virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.Source: Cancer Therapy Advisor
Amer Zeidan, MBBS, MHS, Discusses Efficacy of Azacitdine Plus Durvalumab for AML and MDS
At the 2019 ASH Annual Meeting, Amer M. Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, Connecticut, discusses results from a large, international, randomized phase 2 study exploring azacitidine plus durvalumab for older patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) who are unfit for intensive chemotherapy.Source: Oncology Learning Network
Yale Cancer Center researchers show identifying type of chronic pain in adults with sickle cell disease may lead to better outcomes
Identifying the type of pain an adult with sickle cell disease (SCD) experiences may be useful in improving treatment, according to a new study by researchers at Yale Cancer Center (YCC) and Smilow Cancer Hospital.
Department of Neurology Receives Major Grant to Evaluate Blood Thinners and Stroke Prevention
Yale School of Medicine has received a 5-year, $20 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) to administer a Phase III trial measuring the effectiveness of using a blood thinner to prevent new strokes in patients who suffered brain hemorrhages and have atrial fibrillation, or irregular heartbeat.
Yale Researchers Crack the Code of a Rare, Inherited Anemia
Yale pediatrician and geneticist Patrick Gallagher, M.D., studies hereditary spherocytosis (HS), an inherited disease associated with hemolytic anemia, when red blood cells are destroyed faster than they are produced due to abnormal membranes. A novel mutation in the gene that encodes alpha-spectrin, a protein essential for normal red blood cell membranes, is responsible for many cases of recessive hereditary spherocytosis (rHS), the most severe form of the disease, reports Gallagher’s team
Smilow Cancer Hospital and Yale Cancer Center receive grant from Frederick A. DeLuca Foundation to fund Hematology Research Center
Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) are proud to announce a five-year grant awarded by The Frederick A. DeLuca Foundation to establish The DeLuca Center for Innovation in Hematology Research.